HALO
Halozyme TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
HALO vs peer average
79/100
HALO vs. peer average (B vs. D)
Grade spread
A 1 · C 2 · D 4 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
LGND is the first available peer comparator.
Closest hybrid operating comparator: Ligand combines diversified biopharmaceutical royalty assets with licensed technology platforms used by biopharma partners, overlapping Halozyme's royalty-plus-platform model while differing in technology focus. [Ligand Investor Relations](https://investor.ligand.com/overview/default.aspx)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
HALO
Halozyme Therapeutics
LGND
Ligand
Grade
B
D
Momentum
94
37
Value
66
60
Sentiment
63
37
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs LGND
HALO / LGND
Grade Position
Above peers
HALO vs. peer average (B vs. D)
79/100
Momentum
94
HALOValue
66
HALOSentiment
63
HALORotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs HALO
LGND is the first peer returned for this comparison set.